Bayer AG News Conference Call

Third quarter of 2017:

Bayer: Sales and earnings increased

• Covestro deconsolidated

• Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million

• EBITDA before special items up by 4.1 percent to EUR 2,204 million

• Sales and earnings growth at Pharmaceuticals

• Consumer Health business weak, as expected

• Sales gains at Crop Science and Animal Health

• Net income of EUR 3,881 million including Covestro book profit

• Core earnings per share at EUR 1.47 (minus 3.9 percent)

• Group outlook for 2017 confirmed based on change in structure
  » more

Links

Interim Report Q3 2017

Press kit

Speaker

Follow the coverage in our social media channel:

   Twitter 

   You will find the key statements on » Twitter